Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Pegasys opvejer risiciene til behandling af kronisk hepatitis B og C.
The Committee for Medicinal Products for Human Use (CHMP) decided that Pegasys’ s benefits are greater than its risks for treatment of chronic hepatitis B and C.